临床Ⅱ期鼻咽癌根治性常规分割放疗预后分析

目的 分析临床Ⅱ期鼻咽癌根治性常规分割放疗疗效,探讨进一步提高疗效方法.方法 回顾分析1999年前9年余内首程治疗的216例患者的预后及影响因素.采用直线加速器6 MVX线和9～12 MeV电子线常规分割照射.26例外照射DT70 Gy仍有原发灶残存的,18例接受腔内近距离治疗,8例接受立体定向放疗推量照射.结果 临床Ⅱ期中T2N0M0、T1N1M0和T2N1M0期患者10年总生存率分别为90%、80%和75.2%(χ2=3.26,P=0.200);无瘤生存率分别为79%、60%和62.6%(χ2=5.87,P=0.053);无远处转移生存率分别为90%、74%和68.0%(χ2=7.09,P=0.030).单因素分析显示T分期对总生存(χ2=0.36,P=0.550)、无瘤生存(χ2=0.44,P:0.500)和无远处转移生存(χ2=0.25,P=0.610)的均无影响,N分期影响无瘤生存率(χ2=5.86,P=0.015)和无远处转移生存率(χ2=5.31,P=0.021).多因素分析显示N分期是无瘤生存率(χ2=5.03,P=0.025)和无远处转移生存率(χ2=6.47,P=0.011)的独立预后因素.结论 淋巴结阳性的Ⅱ期鼻咽癌单纯放疗是不够的,应考虑与化疗结合以提高无瘤生存率和降低远处转移.

The outcome of stage Ⅱ nasopharyngeal carcinoma treated by definitive conventional fractionation radiotherapy

Objective To evaluate the outcome of Stage Ⅱ nasopharyngeal carcinoma(NPC) trea-ted by conventional fractionation radiotherapy. Methods From January 1990 to May 1999,216 patients with untreated stage Ⅱ NPC were irradiated by 6 MV photons and 9-12 MeV electrons with linear accelera-tor. Of 26 patients with residual lesions after 70 Gy irradiation, 18 received intracavitary brachytherapy and 8 received stereotactic irradiation boost. Results The 10-year overall survival (OS) of patients with T2 N0 M0, T1N1M0 and T2N1M0 disease were 90%, 80% and 75.2% (χ2 = 3.26, P =0. 200), respectively. The corresponding disease-free survival(DFS) and distant metastasis-free survival(DMFS) were 79% ,60% and 62.6% (χ2 = 5.87, P = 0.053) ;90% ,74% and 68.0% (χ2 = 7.09, P = 0. 030), respectively. In uni-variate analysis, T stage had no impact on OS, DFS or DMFS (χ2 = 0.44, P = 0. 500 ; χ2 = 0.44, P = 0.500 ; χ2 = 0.25, P = 0. 610), while N stage significantly influenced DFS and DM FS (χ2 = 5.86, P = 0. 015 ; χ2 = 5.31 ,P = 0. 021). Multivariate analysis showed that N stage was an independent prognostic factor for DFS and DMFS(χ2=5.03,P=0.025;χ2=6.47,P=0.01). Conclusions Stage Ⅱ NPCwithposifivelymph node treated by radiotherapy alone is inadequate. In order to improve DFS and DMS, combined chemo-radio-therapy should be considered.